Cabazitaxel Accord Európska únia - slovenčina - EMA (European Medicines Agency)

cabazitaxel accord

accord healthcare s.l.u. - cabazitaxel - prostatic neoplasms, kastrácia-odolný - antineoplastické činidlá - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Cabazitaxel Teva Európska únia - slovenčina - EMA (European Medicines Agency)

cabazitaxel teva

teva b.v. - cabazitaxel - prostatické nádory - antineoplastické činidlá - liečba rakoviny prostaty.

Cabazitaxel MSN Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

cabazitaxel msn

msn labs europe limited, malta - kabazitaxel - 44 - cytostatica

Jevtana Európska únia - slovenčina - EMA (European Medicines Agency)

jevtana

sanofi winthrop industrie - cabazitaxel - prostatické nádory - antineoplastické činidlá - jevtana v kombinácii s prednizónom alebo prednizolónom je indikovaná na liečbu pacientov s metastatickým karcinómom prostaty refraktérneho pôvodu, ktorý bol predtým liecený režimom obsahujúcim docetaxel.

Xtandi Európska únia - slovenčina - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatické nádory - endokrinná terapia - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.